Testicular Flashcards
How are testicular tumours classified
Germ cell (50% seminoma and 50% non-seminomatous)
Sex cord stromal cancers
95% of testicular tumours are germ cells (seminoma vs non-seminoma GCT)
5% are sex cord stromal cancers (Lydia & Sertoli)
What types of non-seminomatous germ cell tumour are there
And where do they arise from
Yolk sac, teratoma, chorocarcinoma
Sertoli/Leydig cell
Embryonal
95% are testicular
5% are extra-gonadal (typically midline - retroperitoneum, mediastinum, cerebrum)
What is the risk of future contralateral testicular cancer, if previous testicular cancer
5% increased risk of contralateral disease
What risk factors are there for testicular cancer
Previous testicular cancer - 5% increased risk
FHx - brother = x10, father = x4
Subnormal testicular development - maldescent, Down’s, Klinefelters
Unilateral maldescent = 5-10x increased risk; bilateral maldescent = 1 in 44)
Intra-tubular germ cell neoplasia (Like CIS: 50% risk at 5yrs)
Testicular atrophy or small volume (<12mls)
What is the typical age range for development of testicular cancer
25-35yrs
>60yrs - more likely to be lymphoma
What tumour marker is raised in seminoma
bHCG (in 10-20%)
What tumour marker is not elevated in seminoma
AFP
What tumour markers are raised in non-seminomatous germ cell tumours
bHCG (in 35%) & AFP
What is raised in choriocarcinoma
bHCG - very high
Where is the lymphatic spread for testicular tumours
R - interaortocaval nodes
L - para-aortic nodes
How should a new testicular tumour be investigated
Examination of testes and breast tissue
Bloods - bHCG, AFP, LDH
USS testes
CTCAP, MRI brain
Biopsy (orchidectomy) - note mediastinal primary alone is a poor prognostic marker
consider biopsy of contralateral testis if risk factors (volume <15ml) to exclude ITGCN
Treatment related
Fertility - sperm banking
EDTA (renal function), lung function (bleomycin), audiometry (cisplatin)
What is the first step in management of a testicular cancer, assuming no visceral mets
Orchiectomy and recheck serum markers
Residual retroperitoneal lesions >1cm should be resected by post-chemo RPLND to establish if necrotic or viable tumour is present, and to remove any mature teratoma
How does the presence of visceral mets / decompensation at presentation influence initial management of a testicular cancer
Start with chemo and delay orchiectomy
Residual retroperitoneal lesions >1cm should be resected by post-chemo RPLND to establish if necrotic or viable tumour is present, and to remove any mature teratoma
What is the management of ITGCN if found at biopsy of the contralateral testis (present in 5%)
What proportion progress to malignancy
What are the risks
what is the follow up
RT: 20Gy in 10#
50-100% will progress
Risks: Infertility and need for testosterone replacement
Follow up - annual ultrasound
What is the management of a stage 1 seminoma
How are the risks stratified for stage 1
80% are found at stage one (T1-2 N0 - involvement of tunica albuginea or vaginalis, +/- lymph vascular invasion, no nodes or distant mets)
Orchidectomy has 95% cure rate, so priority is to minimise toxicity
Risk is stratified by size (> 4cm or not) and presence of invasion into the Rete testis
Post orchidectomy, tumour size <4cm and no rete testis involvement: surveillance only
Tumour markers 3/12 for first year
Year 1 -> 3-6 monthly CT, then annual scanning
If >4cm or rete testis involvement - requires adjuvant treatment